We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PSR Orphan Experts launches patient organization advisory board

PSR Orphan Experts launches patient organization advisory board

November 9, 2016
CenterWatch Staff

PSR Orphan Experts, a specialty orphan drug consulting and clinical research company, has announced the launch of a new Patient Organization Advisory Board to bolster its regulatory and clinical-stage drug development services in rare diseases. The advisory board comprises of up to seven experts from patient organizations, representing a wide range of therapeutic areas, and will play a key role in driving successful orphan drug programs for PSR’s clients.

PSR launched the Advisory Board in line with growing recognition, within both biopharmaceutical companies and regulatory agencies, that patients need a greater share of voice in the development of new medicines. Rare disease patients are often experts on their own conditions, and patient groups can be a driving force in pharmaceutical R&D. Members of the advisory board will strengthen PSR’s patient-centric approach in clinical research. They give patients and their representatives greater opportunities to provide input directly into clinical-stage development planning.

The inaugural members of PSR’s Patient Organization Advisory Board are:

  • Oliver Timmis, CEO AKU Society 
  • Elin Haf Davies, child health advocate and Founder of aparito health 
  • Robert Derham, co-founder CheckOrphan 
  • Alasdair Robertson, scientific advisory board member, Duchenne U.K.
  • Alan Thomas, founder of Ataxiaandme.org

“The PSR team is highly engaged with the rare disease cause, with a history of fundraising, providing education and participation in public-private partnerships,” said Chairman of the Patient Organization Advisory Board Dr. Oliver Timmis. “PSR also has a strong track record of successful partnerships with industry, key opinion leaders and patient organizations. Through this new advisory board, we look forward to having an even closer dialogue with the team, to the ultimate benefit of patients and families affected by rare diseases.”

Global News Study Conduct

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing